Last week the FDA approved a new therapy, BESREMi (ropeginterferon alfa-2b-njft) from PharmaEssentia, for the treatment of adults with polycythemia vera (PV). The drug was
The FDA just approved a new ORAL therapy, Scemblix (asciminib) from Novartis, for patients with Philadelphia chromosome-positive chronic myeloid leukemia previously treated with two or
We missed one……. At the end of August the FDA approved a new therapy, Skytrofa from Ascendis Pharma (lonapegsomatropin-tcgd), indicated for pediatric patients that have
Most of us that work in the specialty pharmacy segment are very familiar with the concept of a HUB. At its rudimentary level a HUB
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
The FDA approved a new therapy, Susvimo (ranibizumab injection) from Genentech, indicated for intravitreal use via ocular implant for wet age-related macular degeneration (AMD) with
A little over two years ago we reported on the approval of yet another biosimilar to Humira (yawn), Cyltezo (adalimumab-adbm) a sub-q therapy from Boehringer
Last week we published a review of the 2021 Medication Access Report which detailed a variety of access barriers including COVID-19, logistics, financial burdens, and
We’ve written frequently on two of the biggest trends in channel access, the shift away from buy-and-bill to other, less costly, sites of service as
We all know that the past year has been nothing short of a massive monkey wrench thrown into the US healthcare machinery and the impacts
